Mineralys Therapeutics, Inc.
MLYS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001933414
In the last 90 days, Mineralys Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 225 institutions reported holding it in 13F filings for Q2 2026, worth $2.69B in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Mineralys Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 109
- +3 vs. Q3 2024
- Shares held
- 46.5M
- +2.10M (+4.7%) vs. Q3 2024
- Total value
- $572.2M
- +$32.2M (+6.0%) vs. Q3 2024
- New holders
- 17
- 44 more added
- Sold out
- 14
- 17 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MLYS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 225 | $2.69B |
| Q1 2026 | 215 | $2.46B |
| Q4 2025 | 223 | $3.21B |
| Q3 2025 | 193 | $3.01B |
| Q2 2025 | 166 | $888.8M |
| Q1 2025 | 149 | $966.2M |
| Q4 2024 | 109 | $572.2M |
| Q3 2024 | 106 | $540.1M |
| Q2 2024 | 94 | $516.6M |
| Q1 2024 | 92 | $540.6M |
| Q4 2023 | 87 | $298.5M |
| Q3 2023 | 77 | $252.1M |
| Q2 2023 | 68 | $429.2M |
| Q1 2023 | 68 | $385.4M |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Mineralys Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 1,432,042 | $17.6M | 0.00% | +68,811+5.0% | Added |
| OrbiMed Advisors LLC | 1,611,637 | $19.8M | 0.41% | −391,302−19.5% | Reduced |
| Franklin Resources Inc | 1,745,597 | $21.5M | 0.01% | +840.0% | Added |
| Sr One Capital Management, LP | 2,016,822 | $24.8M | 6.05% | 00.0% | Unchanged |
| BlackRock, Inc. | 2,138,522 | $26.3M | 0.00% | −5,646−0.3% | Reduced |
| TCG Crossover Management, LLC | 2,470,265 | $30.4M | 2.97% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 4,850,984 | $59.7M | 0.79% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 5,074,916 | $62.5M | 8.57% | 00.0% | Unchanged |
| Catalys Pacific, LLC | 8,644,579 | $106.4M | 91.82% | 00.0% | Unchanged |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −600,000−100.0% | Sold out |
| Blue Owl Capital Holdings LP | 0 | $0 | 0.00% | −196,132−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −125,000−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −27,361−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −20,505−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −15,855−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −12,238−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −11,196−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −3,136−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −1,472−100.0% | Sold out |
| Voisard Asset Management Group, Inc. | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| Bokf, NA | 0 | $0 | 0.00% | −25−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −23−100.0% | Sold out |
| Avion Wealth | 0 | $0 | 0.00% | −78−100.0% | Sold out |